Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
asenapine
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Sublingual, Transdermal
01
Overview
Asenapine is an atypical antipsychotic medication used to treat schizophrenia and bipolar I disorder in adults and children aged 10 years and older. It works by balancing brain chemicals such as dopamine and serotonin to improve thinking, mood, and behavior. Asenapine is available in sublingual tablet form (Saphris) and transdermal patch form (Secuado). It acts primarily as a multireceptor antagonist with strong activity at serotonin 5-HT2A receptors and dopamine D2 receptors. Compared to first-generation antipsychotics, it has a lower incidence of extrapyramidal side effects due to its unique receptor profile[2][3][4].
- Brand names
- SaphrisSecuadoSycrest
- Other names
- Asenapinaasenapinum(+-)-asenapine
02
Targets
HTR6 (5-hydroxytryptamine receptor 6)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)ADRA2C (α2C)HTR2A (Serotonin receptor 5-HT2A)HTR7 (5-hydroxytryptamine receptor 7)HRH1 (Histamine H1 Receptor)HTR2C (5-hydroxytryptamine 2C receptor)ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on asenapine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on asenapine.